Pia Abel zur Wiesch
Computational Pharmacology
Job description
Associate Professor and Early Career Chair, The Pennsylvania State University
Visiting Researcher, Institute for Pharmacy, UiT
Young Associate Investigator, NCMM, Nordic EMBL partnership
The 50 latest publications is shown on this page. See all publications in Cristin here →
Publications outside Cristin
A Kunkel*, P Abel zur Wiesch*, RR Nathavitharana, FM Marx, HE Jenkins, T Cohen
BMC infectious diseases 16 (1), 282
Hubbard PT, Chao MC, Abel S, Blondel CJ, Abel zur Wiesch P, Zhou X, Davis BM, and Waldor MK.
PNAS (2016) published ahead of print doi:10.1073/pnas.1601718113.
Cadosch D, Abel zur Wiesch P, Kouyos RD, and Bonhoeffer, S.
PLOS Computational Biology (2016) 12 (3):e1004749.
Salvatore P, Becerra M, Abel zur Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T
Fitness costs of drug-resistance mutations in multidrug resistant M. tuberculosis: a household-based case-control study.
J. Infect. Dis. (2015) pii: jiv347. [Epub ahead of print]
Abel S, Abel zur Wiesch P, Davis BM, and Waldor MK
Analysis of bottlenecks in experimental models of infection.
PLOS PATHOGENS (2015) 11(6):e1004823
Abel zur Wiesch P#, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, and Cohen T
Classic reaction kinetics can explain complex patterns of antibiotic action.
SCI. TRANSL. MED. (2015) 7(287):287ra73
Abel S, Abel zur Wiesch P, Chang H-H, Davis BM, Lipsitch M, and Waldor MK
Sequence tag-based analysis of pathogen population dynamics.
Nature Methods (2015) 12(3):223-6
Kouyos RD, Metcalf CJE, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al.
The path of least resistance: aggressive or moderate treatment?
Proceedings of the Royal Society B: Biological Sciences (2014) 281(1794):20140566
Ocampo PS, Lazar V, Bogos B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pal C, Ackermann M and Bonhoeffer S
Antagonism is prevalent between bacteriostatic and bactericidal antibiotics.
Antimicrobial Agents and Chemotherapy (2014) 58(8):4573-82
Abel zur Wiesch P#*, Kouyos RD*, Abel S, Viechtbauer W, and Bonhoeffer S
Optimal antibiotic treatment in hospitals: meta-analysis and models.
PLOS Pathogens (2014) 10(6):e1004225
Abel S, Bucher T, Nicollier M, Hug I, Kaever V, Abel zur Wiesch P, Jenal U
Bi-modal Distribution of the Second Messenger c-di-GMP Controls Cell Fate and Asymmetry during the Caulobacter Cell Cycle.
PLOS Genetics (2013) 9(9):e1003744
Kouyos RD*, Abel zur Wiesch P*, Bonhoeffer S
On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community.
PLOS Pathogens (2011) 7(4):e1001334.
Kouyos RD, Abel zur Wiesch P, Bonhoeffer S
Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards.
PLOS Computational Biology (2011) 7(3):e1001094.
Abel zur Wiesch P*, Kouyos R*, Engelstädter J, Regoes R, Bonhoeffer S
Population biological principles of resistance evolution in infectious diseases.
Lancet Infectious Diseases (2011) 11(3):236-247.
Bonhoeffer S, Abel zur Wiesch P, and Kouyos RD
Rotating antibiotics does not minimize selection for resistance.
Mathematical Biosciences and Engineering (2010) 7(4):919-922.
Schulz zur Wiesch P#, Engelstädter J, and Bonhoeffer S
Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations.
Antimicrobial Agents and Chemotherapy (2010) 54(5):2085-95
Research interests
Antibiotics, Population Biology, Biochemistry, Pharmacology, Tuberculosis, Infectious Diseases,Public Health, Mathematical Modelling